ENTITY
SK Biopharmaceuticals

SK Biopharmaceuticals (326030 KS)

127
Analysis
Health CareSouth Korea
SK Biopharmaceuticals Co., Ltd. researches and develops new drugs. The Company develops and markets brain disorders treatment drugs, central nervous system disorders treatment drugs, and other products. SK Biopharmaceuticals markets its products worldwide.
more
06 Sep 2024 17:23

Key Flow Trading Opportunities After KRX Suddenly Added POSCO Holdings to the BBIG Battery Mix

This post covers the September rebalancing results for the KRX BBIG Index and dives into the standout flow trading opportunities sparked by the...

Logo
502 Views
Share
31 Jul 2024 13:31

KRX’s September Major Rebalancing Events: Why We Should Focus on KRX BBIG

This post examines flow trading opportunities arising from the KRX BBIG's September rebalancing, focusing on the impact of four stocks in the top...

Logo
274 Views
Share
18 May 2024 01:29

SK Biopharmaceuticals (326030 KS): Resumption of US Sales Growth Raises Hope for Annual Profit

In 1Q24, SK Biopharmaceuticals posted Xcopri U.S. sales of KRW90.9B, up 69% YoY and 17% QoQ. The company remains confident to meet Xcopri annual...

Logo
405 Views
Share
13 Nov 2023 00:25

SK Biopharmaceuticals (326030 KS): Xcopri Sales Hit All-Time High in 3Q23; Operating Loss Narrowed

​SK Biopharmaceuticals reported Xcopri US sales of KRW76B, up 60% YoY and 19% QoQ, driven by accelerating new patients being treated with the drug....

Logo
450 Views
Share
19 Sep 2023 20:06

SK Biopharmaceuticals (326030 KS): Solid Growth in Xcopri US Sales in 2Q23; Operating Loss Narrowed

​In 2Q23, Xcopri U.S. sales grew 57% YoY and 18% QoQ to KRW63B, with operating loss narrowing. SK Biopharmaceuticals entered a licensing agreement...

Logo
420 Views
Share
x